Skip to main content

Table 2 Association analysis of rs3733591 with gout in NZ Māori, EP, WP and Caucasian sample sets and in the FHS cohorta

From: The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity

 

Case genotypesb, n(OR)

 

Control genotypes, n(OR)

     

Sample set

CC

CT

TT

C-allele frequency

CC

CT

TT

C-allele frequency

Genotypic P

Allelic P

P STRAT

Allelic OR, C allele (95% CI)

Māori

101 (0.500)

83 (0.411)

18 (0.089)

0.705

164 (0.500)

138 (0.421)

26 (0.079)

0.710

0.92

0.86

0.93

0.98 (0.74 to 1.28)

EP

119 (0.513)

92 (0.397)

21 (0.091)

0.711

169 (0.506)

139 (0.416)

26 (0.078)

0.714

0.82

0.92

0.80

0.99 (0.76 to 1.28)

WP

39 (0.227)

88 (0.512)

45 (0.262)

0.483

33 (0.239)

57 (0.413)

48 (0.348)

0.446

0.17

0.36

0.65

1.16 (0.84 to 1.59)

NZ Caucasian

217 (0.693)

87 (0.278)

9 (0.029)

0.832

417 (0.656)

196 (0.308)

23 (0.036)

0.810

0.49

0.23

-

1.17 (0.91 to 1.50)

FHS

44 (0.657)

21 (0.313)

2 (0.030)

0.813

3158 (0.670)

1,385 (0.294)

169 (0.036)

0.817

0.92

0.91

-

0.98 (0.63 to 1.51)

ARIC

117 (0.765)

30 (0.196)

6 (0.039)

0.863

4902 (0.704)

1,898 (0.272)

168 (0.024)

0.840

0.07

0.28

-

1.20 (0.86 to 1.67)

  1. aARIC = Atherosclerosis Risk in Communities study; CI = confidence interval; FHS = Framingham Heart Study; OR = odds ratio; EP = Eastern Polynesian; NZ = New Zealand; WP = Western Polynesian PSTRAT = STRAT test for association. bThere was successful genotyping of 202 Māori cases (88%) and 328 Māori controls (96%), 232 EP cases (89%) and 334 EP controls (96%), 172 WP cases (92%) and 138 WP controls (97%) and 313 NZ Caucasian cases (96%) and 636 NZ Caucasian controls (100%).